AbbVie Inc. $ABBV Shares Bought by Envestnet Portfolio Solutions Inc.

Envestnet Portfolio Solutions Inc. grew its stake in shares of AbbVie Inc. (NYSE:ABBV) by 7.6% in the 2nd quarter, Holdings Channel reports. The institutional investor owned 89,324 shares of the company’s stock after buying an additional 6,327 shares during the quarter. Envestnet Portfolio Solutions Inc.’s holdings in AbbVie were worth $22,478,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also made changes to their positions in the company. ACT Advisors LLC. grew its position in AbbVie by 2.5% during the second quarter. ACT Advisors LLC. now owns 1,688 shares of the company’s stock valued at $425,000 after acquiring an additional 41 shares during the period. Willner & Heller LLC increased its stake in AbbVie by 0.7% during the second quarter. Willner & Heller LLC now owns 5,852 shares of the company’s stock worth $1,472,000 after acquiring an additional 43 shares during the last quarter. B.O.S.S. Retirement Advisors LLC raised its holdings in shares of AbbVie by 3.1% in the 2nd quarter. B.O.S.S. Retirement Advisors LLC now owns 1,427 shares of the company’s stock worth $359,000 after purchasing an additional 43 shares during the period. Fielder Capital Group LLC raised its holdings in shares of AbbVie by 1.7% in the 2nd quarter. Fielder Capital Group LLC now owns 2,532 shares of the company’s stock worth $637,000 after purchasing an additional 43 shares during the period. Finally, Guardian Wealth Advisors LLC NC lifted its stake in shares of AbbVie by 0.4% in the 2nd quarter. Guardian Wealth Advisors LLC NC now owns 11,906 shares of the company’s stock valued at $2,996,000 after purchasing an additional 43 shares in the last quarter. 70.23% of the stock is currently owned by institutional investors and hedge funds.

Trending Headlines about AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Rinvoq wins EU approval for pediatric arthritis: The European Commission approved Rinvoq for children aged two and older with active polyarticular juvenile idiopathic arthritis who have not responded adequately to, or cannot tolerate, at least one DMARD. The approval adds a new pediatric use, includes an oral solution, and brings Rinvoq to 11 approved indications in Europe. The commercial impact is likely modest initially, but the decision expands the drug’s addressable population and reinforces its growth potential. AbbVie Announces European Commission Approval of Rinvoq
• Positive Sentiment: Potential pipeline collaboration: Iambic reportedly filed for an IPO after signing AbbVie as a partner. Although financial terms and the specific assets involved were not provided, the arrangement could give AbbVie access to additional computational drug-discovery capabilities and future pipeline opportunities. Iambic files IPO after signing AbbVie as new partner
• Neutral Sentiment: Aesthetic business initiatives: Allergan Aesthetics launched AA Signature with SKIN360 in the United States, a multimodal consultation and provider-education program. The initiative may support customer engagement and procedure demand, but no immediate revenue impact was disclosed. Allergan Aesthetics Debuts AA Signature
• Negative Sentiment: Bearish analyst commentary: A Seeking Alpha analysis argues that revenue pressure and weakening earnings support a “sell” view. This contrasts with AbbVie’s latest reported quarterly revenue growth and earnings beat, but highlights investor concerns over the sustainability of growth and the stock’s elevated valuation. AbbVie: Revenue Pressure And Weakening Earnings Support a Sell

AbbVie Stock Performance

Shares of ABBV stock traded up $0.22 during trading hours on Wednesday, reaching $265.43. The company had a trading volume of 3,445,647 shares, compared to its average volume of 6,531,572. The company has a market capitalization of $468.96 billion, a P/E ratio of 74.98, a price-to-earnings-growth ratio of 1.19 and a beta of 0.29. AbbVie Inc. has a twelve month low of $190.75 and a twelve month high of $269.39. The stock’s fifty day simple moving average is $256.31 and its 200 day simple moving average is $232.58.

AbbVie (NYSE:ABBV) last released its quarterly earnings results on Friday, July 31st. The company reported $3.65 EPS for the quarter, topping the consensus estimate of $3.61 by $0.04. The firm had revenue of $16.99 billion for the quarter, compared to analyst estimates of $16.80 billion. AbbVie had a negative return on equity of 422.07% and a net margin of 9.80%.AbbVie’s revenue for the quarter was up 10.2% on a year-over-year basis. During the same period in the previous year, the company posted $2.97 EPS. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. As a group, equities analysts expect that AbbVie Inc. will post 14.05 earnings per share for the current year.

AbbVie Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Monday, November 16th. Stockholders of record on Thursday, October 15th will be given a dividend of $1.73 per share. This represents a $6.92 dividend on an annualized basis and a dividend yield of 2.6%. The ex-dividend date of this dividend is Thursday, October 15th. AbbVie’s payout ratio is presently 195.48%.

Analyst Ratings Changes

ABBV has been the subject of a number of research reports. Bank of America reiterated a “buy” rating on shares of AbbVie in a report on Tuesday, September 8th. HSBC lifted their price target on shares of AbbVie from $300.00 to $315.00 and gave the company a “buy” rating in a research report on Thursday, September 10th. Wolfe Research upgraded shares of AbbVie from a “peer perform” rating to an “outperform” rating and set a $300.00 price objective for the company in a research note on Thursday, August 13th. JPMorgan Chase & Co. increased their price objective on shares of AbbVie from $260.00 to $280.00 and gave the stock an “overweight” rating in a research report on Thursday, July 9th. Finally, BNP Paribas Exane raised their target price on shares of AbbVie from $218.00 to $247.00 and gave the company a “neutral” rating in a research note on Tuesday, August 11th. Two equities research analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and five have assigned a Hold rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $276.64.

Insider Buying and Selling at AbbVie

In other news, EVP Nicholas Donoghoe sold 32,710 shares of the company’s stock in a transaction on Friday, August 14th. The shares were sold at an average price of $250.00, for a total value of $8,177,500.00. Following the completion of the transaction, the executive vice president directly owned 74,430 shares in the company, valued at approximately $18,607,500. This represents a 30.53% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Company insiders own 0.06% of the company’s stock.

AbbVie Profile

AbbVie Inc (NYSE: ABBV) is a global biopharmaceutical company that discovers, develops and commercializes medicines across immunology, oncology, neuroscience, eye care, aesthetics and other specialty areas. The company was established in 2013 after separating from Abbott Laboratories, which retained Abbott’s diversified medical products and diagnostics businesses while AbbVie focused on research-based pharmaceuticals.

AbbVie’s immunology portfolio includes Skyrizi (risankizumab) and Rinvoq (upadacitinib), which are used to treat several inflammatory conditions.